当前位置:首页>产品中心>单抗/多抗>Anti-Mouse SLC22A5 Polyclonal Antibody|抗小鼠SLC22A5多克隆抗体(靶标:小鼠溶质载体家族22成员5/OCTN2)

Anti-Mouse SLC22A5 Polyclonal Antibody|抗小鼠SLC22A5多克隆抗体(靶标:小鼠溶质载体家族22成员5/OCTN2)

  • 货号:RB9TMF955014
  • 价格:面议
  • 点击:619
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Mus musculus (Mouse)
靶标High-affinity sodium-dependent carnitine cotransporter, OCTN2, Organic cation/carnitine transporter 2, SLC22A5, Solute carrier family 22 member 5
免疫原E. coli - derived recombinant Mouse SLC22A5 (Leu42-Ala142&Glu279-Arg341).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q9Z0E8
背景信息

Organic cation/carnitine transporter 2 (SLC22A5) is a ~62 kDa protein. Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.

1. Wu, X. et al. (1999) The Journal of pharmacology and experimental therapeutics 290, 1482-92. PMID: 10454528
2. Fujiya, M. et al. (2011) Inflammatory bowel diseases 17, 907-16. PMID: 20722056
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 692
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 680
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 645
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 630
Anti-Durvalumab Non-Neutralizing Recombinant Antibody |程度伐利尤单抗非中和重组抗体(靶标:度伐利尤单抗非中和抗体) 975
Anti-Durvalumab Non-Neutralizing Recombinant Antibody |抗度伐利尤单抗非中和重组抗体(靶标:度伐利尤单抗非中和抗体) 867
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 698
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 787
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 721
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 721
Anti-Atezolizumab Non-Neutralizing Recombinant Antibody |抗阿替利珠单抗非中和重组抗体(靶标:阿替利珠单抗非中和抗体) 729
Anti-Atezolizumab Non-Neutralizing Recombinant Antibody |抗阿替利珠单抗非中和重组抗体(靶标:阿替利珠单抗非中和抗体) 682
Anti-Atezolizumab Neutralizing Recombinant Antibody |抗阿替利珠单抗中和重组抗体(靶标:阿替利珠单抗中和抗体) 638
Anti-Atezolizumab Neutralizing Recombinant Antibody |抗阿替利珠单抗中和重组抗体(靶标:阿替利珠单抗中和抗体) 779
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 904
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 659
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 649
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 591
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 631
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 604
总计 33037 个记录,共 1652 页,当前第 1647 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30